Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria - PubMed (original) (raw)

Randomized Controlled Trial

Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria

G S Humphreys et al. Antimicrob Agents Chemother. 2007 Mar.

Abstract

The artemisinin-based combination therapies artemether-lumefantrine (AL) and amodiaquine (AQ) plus artesunate have been adopted for treatment of Plasmodium falciparum malaria in many African countries. Molecular markers of parasite resistance suitable for surveillance have not been established for any of the component drugs in either of these combinations. We assessed P. falciparum mdr1 (Pfmdr1) alleles present in 300 Tanzanian children presenting with uncomplicated falciparum malaria, who were enrolled in a clinical trial of antimalarial therapy. Pfmdr1 genotype analysis was also performed with isolates from 182 children who failed AQ monotherapy and 54 children who failed AL treatment. Pfmdr1 alleles 86Y, 184Y, and 1246Y were more common among treatment failures in the AQ group than among pretreatment infections. The converse was found in the AL-treated group. Children presenting with the 86Y/184Y/1246Y Pfmdr1 haplotype and treated with AQ were significantly more likely to retain this haplotype if they were parasite positive during posttreatment follow-up than were children treated with AL (odds ratio, 33.25; 95% confidence interval, 4.17 to 1441; P, <0.001). We conclude that AL and AQ exert opposite within-host selective effects on the Pfmdr1 gene of P. falciparum.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Pretreatment random baseline prevalence of Pf_crt_ and Pf_mdr1_ alleles. The white portion of the bars shows the prevalence of the alleles associated with CQ sensitivity. The black portion shows the prevalence of alleles associated with CQ resistance. The gray portion shows the prevalence of samples where a mixed infection containing both alleles was detected.

FIG. 2.

FIG. 2.

Prevalence of pre- and posttreatment Pf_mdr1_ alleles following therapy with either AQ or AL. Mixed infections are shown as separate columns in the middle of each graph. The number of samples involved in each prevalence calculation is shown in the legend in each graph.

Similar articles

Cited by

References

    1. Djimde, A., O. K. Doumbo, J. F. Cortese, K. Kayentao, S. Doumbo, Y. Diourte, A. Dicko, X. Z. Su, T. Nomura, D. A. Fidock, T. E. Wellems, C. V. Plowe, and D. Coulibaly. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:257-263. - PubMed
    1. Dokomajilar, C., S. L. Nsobya, B. Greenhouse, P. J. Rosenthal, and G. Dorsey. 2006. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 50:1893-1895. - PMC - PubMed
    1. Reference deleted.
    1. Duraisingh, M. T., P. Jones, I. Sambou, L. von Seidlein, M. Pinder, and D. C. Warhurst. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108:13-23. - PubMed
    1. Famin, O., and H. Ginsburg. 2002. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Biochem. Pharmacol. 63:393-398. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources